About bsbh

This author has not yet filled in any details.
So far bsbh has created 117 blog entries.

Advanced Therapies – Opportunities and Challenges – Report

Advanced Therapies – Opportunities and Challenges 14th November, London Presentations Click on the name of the speaker to download the slide deck Keynote Session: “The Future of Advanced Therapies” Peter Goodfellow, Scientific Advisor, Abingworth “Regenerating the Future, Again” Lord James O’Shaughnessy, [...]

Advanced Therapies – Opportunities and Challenges – Report 2017-11-16T14:12:59+00:00

Advanced Therapies – Opportunities and Challenges – Presentations

Organised in partnership with: Advanced Therapies – Opportunities and Challenges 14th November, London Presentations Click on the name of the speaker to download the slide deck Keynote Session: “The Future of Advanced Therapies” Peter Goodfellow, [...]

Advanced Therapies – Opportunities and Challenges – Presentations 2017-11-21T15:34:39+00:00

Michaël Hocquemiller

Michaël Hocquemiller, PhD Scientific Director, Lysogene   Michaël Hocquemiller is scientific director at Lysogene. He has 10 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Hocquemiller has co-led the Phase 1 clinical trial in MPS IIIA, as well as designing drug candidates and [...]

Michaël Hocquemiller 2017-11-13T09:11:29+00:00

Samantha Parker

Samantha Parker Chief Patient Officer Lysogene   Samantha Parker is Chief Patient Officer at Lysogene, with more than 20 years’ experience in the pharmaceutical industry: executive and management, strategic leadership, vice president of a foundation for independent professional education in rare diseases, global drug development & patient access across several rare disease [...]

Samantha Parker 2017-10-25T13:51:57+00:00

Gabriele Proetzel

Gabriele Proetzel, Ph.D. Director, Regenerative Medicine, Takeda Gabriele Proetzel, PhD is Director of Regenerative Medicine at Takeda Pharmaceuticals, based in Cambridge, MA. In her current role she is focused on cell and gene therapy therapeutic approaches and strategic alliance management. Prior industry appointments were Chief Scientific Officer at Scil Proteins, Halle Germany, [...]

Gabriele Proetzel 2017-10-12T07:10:48+00:00

Christian Schneider

Dr Christian K Schneider Director of National Institute for Biological Standards and Control (NIBSC) Dr Christian Schneider joined the National Institute for Biological Standards and Control (NIBSC) in January 2016, taking over as Director in April 2016. NIBSC is a centre of the Medicines and Healthcare products Regulatory Agency (MHRA). Christian is [...]

Christian Schneider 2017-10-11T15:12:58+00:00

Lord James O’Shaughnessy

Lord James O'Shaughnessy Parliamentary Under Secretary of State for Health (Lords), UK Government   Lord O’Shaughnessy was appointed as a Parliamentary Under Secretary of State at the Department of Health and a Government Whip (Lord in Waiting) in December 2016. Lord O’Shaughnessy was a senior fellow at the Legatum Institute and at [...]

Lord James O’Shaughnessy 2017-10-11T11:11:06+00:00

Karen Hodgkin

Karen Hodgkin COO, Chief Operating Officer, Cell Medica Karen has over 30 years of experience in planning and running clinical trials. After joining Cell Medica in early 2008 to lead the Clinical Operations and Regulatory functions, Karen moved to become Cell Medica’s COO in September 2016. In the past, Karen has worked [...]

Karen Hodgkin 2017-10-25T13:45:20+00:00

Peter Goodfellow

Professor Peter Goodfellow FMedSci FRS, Scientific Advisor, Abingworth Peter Goodfellow is a geneticist who tracked down the genetic essence of human ‘maleness’. In a high-profile scientific race to find the enigmatic ‘testis-determining factor’ (TDF; also known as sex-determining region Y (SRY) protein), Peter overturned others’ claims by correctly pinpointing the tiny SRY [...]

Peter Goodfellow 2017-09-25T10:50:23+00:00